Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of IL-YANG Quadrivalent Influenza Vaccine in Healthy Adults
NCT02677493Phase 3Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of influenza virus vaccine quadrivalent in influenza (3 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Rate of Healthy Adults Aged ≥19 Years With Seroconversion at Day 28 and Rate of Healthy Adults Aged ≥19 Years With Seroprotection at Day 28. Started Oct 2015; status: completed.
02
Drugs
influenza virus vaccine quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02677493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677493.